Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cost-effectiveness of CYP2C19 guided treatment with antiplatelet drugs in patients with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention with stent implantation: Optimization of treatment.

Next Previous
Trial Profile

Cost-effectiveness of CYP2C19 guided treatment with antiplatelet drugs in patients with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention with stent implantation: Optimization of treatment.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clopidogrel (Primary) ; Prasugrel (Primary) ; Ticagrelor (Primary) ; Aspirin
  • Indications Acute coronary syndromes; Coronary artery restenosis; Myocardial infarction; Stent thrombosis
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms POPGenetics; POPular Genetics

Most Recent Events

  • 07 Sep 2021 Results assessing cost effectiveness of a genotype-guided strategy compared with standard treatment with ticagrelor or prasugrel, published in the American Journal of Cardiovascular Drugs.
  • 01 Jul 2021 Results of a pre-specified sub analysis (n=991) from the POPular Genetics and POPular Age trials assessing the effect of CYP2C19 loss-of-function alleles in clopidogrel treated elderly patients, published in the International Journal of Cardiology.
  • 17 May 2021 Results (N=4480) of Bayesian analysis of randomized clinical trials (RCTs) to assess the role of genotype-guided P2Y12 inhibitor therapy after PCI using data from TAILOR-PCI trial) and 2) informative priors (derived from ADAPT, POPular Genetics, IAC-PCI, PHARMCLO RCTs presented at the 70th Annual Scientific Session of the American College of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top